| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile …
Over the last 12 months, insiders at Anavex Life Sciences Corp. have bought $0 and sold $0 worth of Anavex Life Sciences Corp. stock.
On average, over the past 5 years, insiders at Anavex Life Sciences Corp. have bought $32,919 and sold $989,094 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,835 shares for transaction amount of $10,319 was made by Donhauser Peter D.O. (director) on 2024‑06‑14.
| 2024-06-14 | Donhauser Peter D.O. | director | 2,835 0.0033% | $3.64 | $10,319 | +114.06% | ||
| 2024-05-15 | Thomas Steffen | director | 5,000 0.0059% | $4.52 | $22,600 | +72.49% | ||
| 2024-03-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 73,380 0.0911% | $5.11 | $374,972 | +19.55% | |
| 2023-06-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 268,000 0.3424% | $7.98 | $2.14M | -24.69% | |
| 2022-05-25 | Sale | Skarpelos Athanasios | 50,000 0.0643% | $9.06 | $453,000 | +8.46% | ||
| 2021-06-29 | Sale | MISSLING CHRISTOPHER U | President and CEO | 51,620 0.0805% | $26.00 | $1.34M | -28.27% | |
| 2021-06-29 | Sale | Boenisch Sandra | PFO and Treasurer | 166,696 0.2651% | $26.53 | $4.42M | -28.27% | |
| 2021-05-21 | Sale | FAVUS ELLIOT | director | 145,000 0.2057% | $11.70 | $1.7M | +49.44% | |
| 2021-05-17 | Donhauser Peter D.O. | director | 1,000 0.0014% | $10.93 | $10,930 | +54.43% | ||
| 2021-02-24 | Sale | FAVUS ELLIOT | director | 145,500 0.2172% | $12.66 | $1.84M | +40.94% | |
| 2021-02-19 | Donhauser Peter D.O. | director | 1,165 0.0017% | $12.67 | $14,760 | +38.92% | ||
| 2018-03-07 | MISSLING CHRISTOPHER U | President and CEO | 1,360 0.0031% | $2.92 | $3,971 | -13.15% | ||
| 2018-03-06 | MISSLING CHRISTOPHER U | President and CEO | 1,450 0.003% | $2.73 | $3,959 | -14.33% | ||
| 2018-03-05 | MISSLING CHRISTOPHER U | President and CEO | 1,500 0.0034% | $2.63 | $3,945 | -4.20% | ||
| 2018-03-02 | MISSLING CHRISTOPHER U | Director, President & CEO | 1,650 0.0034% | $2.41 | $3,977 | -3.85% | ||
| 2017-10-25 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.39 | $1,646 | -36.81% | ||
| 2017-10-24 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.92 | $1,845 | -41.40% | ||
| 2017-10-19 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0008% | $4.49 | $1,684 | -40.47% | ||
| 2017-10-17 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.27 | $1,601 | -34.35% | ||
| 2017-10-13 | MISSLING CHRISTOPHER U | President and CEO | 750 0.0017% | $4.22 | $3,165 | -34.58% |
| Skarpelos Athanasios | 1306458 1.4094% | $1.57M | 1 | 6 | ||
| MISSLING CHRISTOPHER U | President and CEO | 1250210 1.3487% | $1.5M | 39 | 3 | +42.64% |
| Thomas Steffen | director | 5000 0.0054% | $6,000.00 | 1 | 0 | +72.49% |
| Donhauser Peter D.O. | director | 5000 0.0054% | $6,000.00 | 3 | 0 | +69.14% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
Anavex Life Sciences Corp. (AVXL) | $130,095 | 43 | 45.19% | $111.24M |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 89 | +41.4% | 8M | +23.27% |
| Decreased Positions | 86 | -40% | 2M | -7.27% |
| New Positions | 28 | New | 2M | New |
| Sold Out Positions | 31 | Sold Out | 944,254 | Sold Out |
| Total Postitions | 218 | +1.4% | 38M | +16% |
| Blackrock, Inc. | $26,453.00 | 8.08% | 7.19M | +186,507 | +2.66% | 2025-09-30 |
| Vanguard Group Inc | $18,785.00 | 5.74% | 5.1M | -2,357 | -0.05% | 2025-09-30 |
| State Street Corp | $12,097.00 | 3.69% | 3.29M | +338,310 | +11.47% | 2025-09-30 |
| Geode Capital Management, Llc | $7,461.00 | 2.28% | 2.03M | +7,532 | +0.37% | 2025-09-30 |
| Two Sigma Investments, Lp | $3,816.00 | 1.17% | 1.04M | +63,685 | +6.54% | 2025-09-30 |
| Nwam Llc | $3,217.00 | 0.98% | 874,283 | -150,196 | -14.66% | 2025-09-30 |
| Northern Trust Corp | $2,845.00 | 0.87% | 773,012 | -4,153 | -0.53% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,791.00 | 0.85% | 758,500 | -64,900 | -7.88% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $2,640.00 | 0.81% | 717,378 | +7,762 | +1.09% | 2025-09-30 |
| Susquehanna International Group, Llp | $2,222.00 | 0.68% | 603,818 | -2,849 | -0.47% | 2025-09-30 |